In addition to the Director and Deputy Director, the senior leadership of DF/HCC includes nine Associate Directors and thirteen Deputy Associate Directors (some of whom serve in more than one role). The Associate Directors have oversight and coordination responsibility for: Basic Science, Clinical Science, Population Science, Core Facilities, Planning and Evaluation, Development, Membership, and Administration. The Deputy Associate Director assists the respective Associate Director in his/her duties and is available to assume these duties should the Associate Director be unable to serve. These senior leaders meet every other week as the DF/HCC Executive Committee (EC), whose functions are described in Section 6.0 Organizational Capabilities. Six of these individuals also serve as Institutional Representatives. Dr. Fred Alt is the Institutional Representative for Children's Hospital Boston but does not currently serve as an Associate Director or Deputy Associate Director for the DF/HCC. Dr. Alt does participate as a member of the Executive Committee. Since the seven independent institutions participating in DF/HCC have different cultures as well as different locations, the primary responsibility of the Institutional Representative is for communication. In particular, they insure that the DF/HCC members within their institutions are aware of all activities, policies and procedures of the Cancer Center, and that the Center leadership is made aware of any issues from their institution. In addition, they are responsible for the day-to-day representation of the interests of DF/HCC at their institution, and the interests of their institution within DF/HCC. (Members of the Governance Committee have the ultimate responsibility for such institutional interests.)
| Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404 |
| Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917 |
| Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121 |
| Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538 |
| Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228 |
| Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609 |
| McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25 |
| Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233 |
| Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252 |
| Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62 |
Showing the most recent 10 out of 411 publications
